Investor profile
ARCH Venture Partners
VC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
ARCH Venture Partners co-founds and builds breakthrough life sciences and deep-science companies alongside university researchers and leading scientists. As stated on their website: 'We are not interested in following the crowd. We are contrarian, bold, and imaginative risk takers. We follow the science to found companies based on revolutionary technologies that can impact people's lives.' ARCH takes a long-term view, backing companies from concept stage through commercialization — investing as little as $50K at formation and as much as hundreds of millions per company over time — with a particular focus on technologies that prevent, detect, and cure disease. The firm is a recognized leader in commercializing innovations from academic institutions, corporate research groups, and national laboratories, and believes AI and new data-driven insights into biology will help enable a more preventive, curative, and equitable healthcare system.
Notable quotes
“After more than 38 years, the ARCH investment philosophy has been consistent: we bet on great science and great teams to build breakthrough companies. We believe AI and new data-driven insights into biology will help to enable a more preventive, curative and equitable healthcare system. ARCH intends to continue driving the healthcare revolution.”
“ARCH is unique in its ability to see the waves before they start to form. They were the initial glue that brought our scientific founders and investors together to form Agios. ARCH bet on new biology, put the right people, talent, and money together, and was interested in building for the long-term, not a quick flip.”
“There is no other venture firm like ARCH. They are truly unique when it comes to taking real risk to tackle big challenges. Their desire to take on large medical problems, regardless of past failures, knowing that we can succeed in these areas and make an enormous difference, is unprecedented.”
Team
Mark McDonnell
Managing Director, CFO & CAO
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Xaira Therapeutics | Seed/Series A | $1.0b | 2024-04-01 |
| Treeline Biosciences | Series A | $200m | 2025-01-01 |
| Tenvie Therapeutics | Series A | $200m | 2025-01-01 |
| Kardigan | Series B | $254m | 2025-01-01 |
| Ollin Biosciences | Series A | $100m | 2025-01-01 |
| Insitro | Series C | $400m | 2022-01-01 |
| Beam Therapeutics | Series A | $87m | 2019-01-01 |
| Illumina | Seed | — | 1999-01-01 |
| GRAIL | Series A | $100m | 2016-01-01 |
| Alnylam Pharmaceuticals | Series A | — | 2002-01-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Third Rock Ventures | 12 |
| Atlas Venture | 10 |
| Flagship Pioneering | 8 |
| Alexandria Venture Investments | 7 |
| Polaris Partners | 6 |
| a16z Bio | 5 |
Fit check
Is ARCH Venture Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit